Vertex cleared to enter clinic with mRNA therapy VX-522 for cystic fibrosis
Dec. 13, 2022
Vertex Pharmaceuticals Inc. has received clearance from the FDA for its IND application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF).